Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition

Fig. 3

Overexpression of PDIA3P1 counteracted TMZ treatment-induced DNA damage and growth inhibition. A Representative images and quantification of comet assay on ov-PDIA3P1 or Vector U251 and LN229 cells with or without TMZ treatment (400 μM, 48 h). Scale bar, 100 μm. B Representative images and quantification of γ-H2AX staining on ov-PDIA3P1 or Vector U251 and LN229 cells with or without TMZ treatment (400 μM, 48 h). Scale bar, 10 μm. C Representative images of U251 cells subjected to the EdU cell proliferation assay (left panel; scale bar, 100 μm) and quantification of EdU-positive cells (right panel) with or without TMZ treatment (400 μM, 48 h). D Apoptosis assay showing the effect of PDIA3P1 overexpression on U251 with or without TMZ treatment (400 μM, 48 h). The right panel was the quantification of apoptosis cells

Back to article page